PP-C8 is a selective PROTAC that targets the degradation of the CDK12-Cyclin K complex. By facilitating the removal of these proteins, PP-C8 enhances the potential for synergistic effects when used in combination with PARP inhibitors, particularly in the context of triple-negative breast cancer.
Usually ships within 24 hours.